At one time $AMBS was going to sell ELTO PHARMA t
Post# of 109
(Total Views: 333)
Posted On: 04/23/2020 2:27:13 AM
At one time $AMBS was going to sell ELTO PHARMA to
COEPTIS.
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
https://www.amarantus.com/news/press-releases...lto-pharma
Keep an eye on this.
Modi might be back in play.
Could mean big moves coming in the space.
Elto Pharma, Inc. is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer’s disease and adult attention deficit hyperactivity disorder (adult ADHD).
Quick facts
The drug has displayed good oral bioavailability,
It is crosses the Blood brain barrier.
THC, Cannabinoids, CBD all cross the BB as well.
Not only do they cross there is a study that they can help others drugs pass as well
CUREfilm™ Hemp delivers hemp extracts via our CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
That plus the Patent
Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine in combination with a number of chemical compounds, including cannabidiol (CBD) in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034.
The notice of allowance from the EPO underscores the potential for eltoprazine in combination with CBD, or chemical compounds, to treat Parkinson’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus and interim-CEO of Elto Pharma. “The potential for cannabinoid pharmaceuticals is rooted in their potentially synergistic effects with other traditional pharmaceutical compounds, such as eltoprazine. We are very pleased with this first notice of allowance that we’ve received from this international patent family, and we expect to receive many more in the months from jurisdictions around the world, including the United States.”
https://www.amarantus.com/news/press-releases...-notice-of
There's another connect between $AMBS that owns HEMPORI & its partnership with $EMOR.
COEPTIS.
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
https://www.amarantus.com/news/press-releases...lto-pharma
Keep an eye on this.
Modi might be back in play.
Could mean big moves coming in the space.
Elto Pharma, Inc. is developing eltoprazine, an oral small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), aggression in Alzheimer’s disease and adult attention deficit hyperactivity disorder (adult ADHD).
Quick facts
The drug has displayed good oral bioavailability,
It is crosses the Blood brain barrier.
THC, Cannabinoids, CBD all cross the BB as well.
Not only do they cross there is a study that they can help others drugs pass as well
CUREfilm™ Hemp delivers hemp extracts via our CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
That plus the Patent
Elto Pharma, Inc. has received a notice of allowance from the European Patent Office (EPO) covering the use of eltoprazine and eltoprazine in combination with a number of chemical compounds, including cannabidiol (CBD) in the treatment of Parkinson’s disease and Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Once issued, the patent will protect the use of eltoprazine in the treatment of Parkinson’s and PD-LID through 2034.
The notice of allowance from the EPO underscores the potential for eltoprazine in combination with CBD, or chemical compounds, to treat Parkinson’s disease,” said Gerald E. Commissiong, President & CEO of Amarantus and interim-CEO of Elto Pharma. “The potential for cannabinoid pharmaceuticals is rooted in their potentially synergistic effects with other traditional pharmaceutical compounds, such as eltoprazine. We are very pleased with this first notice of allowance that we’ve received from this international patent family, and we expect to receive many more in the months from jurisdictions around the world, including the United States.”
https://www.amarantus.com/news/press-releases...-notice-of
There's another connect between $AMBS that owns HEMPORI & its partnership with $EMOR.
(0)
(0)Currenc Group Inc. (CURR) Stock Research Links
Scroll down for more posts ▼